Product Description
Tiotropium is used to prevent wheezing, shortness of breath, coughing, and chest tightness in patients with chronic obstructive pulmonary disease (COPD, a group of diseases that affect the lungs and airways) such as chronic bronchitis (swelling of the air passages that lead to the lungs) and emphysema (damage to air sacs in the lungs). Tiotropium is in a class of medications called bronchodilators. It works by relaxing and opening the air passages to the lungs to make breathing easier. (Sourced from: https://medlineplus.gov/druginfo/meds/a604018.html)
Mechanisms of Action: LAM Antagonist,MR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Spasm | Chronic Obstructive Pulmonary Disease | Asthma | Chronic Obstructive Pulmonary Disease
Known Adverse Events: Pharyngitis | Sinusitis | Back Pain | Pain Unspecified | Nasopharyngitis
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Finland, India, Switzerland, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Asthma|Chronic Obstructive Pulmonary Disease|Respiratory Aspiration
Phase 2: Bronchopulmonary Dysplasia
Phase 1: Bronchitis, Chronic|Dyspnea|Emphysema|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| STXA-BE-04 | P1 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
2024-08-01 |
|
| STXA-BE-03 | P1 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
2024-03-01 |
53% |
| ARBORUS | P3 |
Completed |
Chronic Obstructive Pulmonary Disease|Respiratory Aspiration |
2023-08-11 |
|
| TIPP | P3 |
Active, not recruiting |
Asthma |
2022-12-28 |